Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons

Ryom, Lenea; Mocroft, Amandab; Lundgren, Jens D.a

Current Opinion in HIV & AIDS:
doi: 10.1097/COH.0000000000000023
DOES ANTIRETROVIRAL TREATMENT AT HIGH CD4 COUNTS REDUCE DISEASE RISK FOR HIV-POSITIVE PATIENTS?: Edited by Jason V. Baker and Caroline A. Sabin
Abstract

Purpose of review: The purpose of this article is to review recent literature on antiretroviral treatment (ART) and immune suppression as risk factors for renal impairment in HIV-positive persons, and to discuss pending research questions within this field.

Recent findings: Several individual antiretroviral agents (ARVs) including tenofovir and several protease inhibitors have, in diverse study settings, been associated with renal impairment. Traditional renal risk factors are common among those experiencing adverse renal impairment to ARVs, but do not fully explain why only some develop these effects. Discontinuation of nephrotoxic ARVs is common with declining renal function, but has unknown long-term consequences. Immune suppression is a strong independent risk factor for renal impairment, and ongoing investigations will clarify whether initiating ARVs with nephrotoxic properties at higher CD4 cell counts will have net beneficial effects on renal function.

Summary: With improvements in survival, multiple risk factors have emerged for renal impairment in HIV-positive persons. Although certain ARVs may cause moderate renal impairment, effects on more severe renal impairment remain unresolved. Regular renal function monitoring allow for switching away from nephrotoxic ARVs in case of decreasing function. If such actions prove beneficial higher prevalence of ARV-associated severe renal impairment may emerge in populations without access to regular monitoring.

Author Information

aCopenhagen HIV Programme and Epidemiklinikken, Copenhagen University Hospital/Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

bResearch Department of Infection and Population Health, UCL, London, United Kingdom

Correspondence to Lene Ryom, Copenhagen HIV Programme, Epidemiklinikken M5132, Copenhagen University Hospital/Rigshospitalet University of Copenhagen, The Panum Institute, Building 21.1, Blegdamsvej 3B, 2200 Copenhagen N, Denmark. Tel: +45 35 45 57 57; fax: +45 35 45 57 58; e-mail: lrn@cphiv.dk

© 2014 Lippincott Williams & Wilkins, Inc.